Skip to main content
. 2023 Jan 16;12(1):127–140. doi: 10.21037/tlcr-22-852

Table 3. Logistic regression analysis of ORR in NSCLC patients treated with camrelizumab.

Variables Univariate analysis Multivariate analysis
OR (95% CI) P OR (95% CI) P
Camrelizumab treatment line
   First line Ref
   Second line 0.278 (0.133–0.583) 0.001 0.347 (0.162–0.741) 0.006
   ≥ Third line 0.121 (0.042–0.35) <0.001 0.126 (0.043–0.367) <0.001
Age
   <70 years Ref
   ≥70 years 0.941 (0.529–1.674) 0.837
Sex
   Male Ref
   Female 0.649 (0.382–1.103) 0.11
Histology
   Adenocarcinoma Ref
   Squamous cell carcinoma 1.543 (0.982–2.425) 0.06
   Other/unspecified 2.739 (0.747–10.038) 0.128
Smoking status
   Never Ref
   Current/former 1.154 (0.726–1.834) 0.544
Brain metastasis
   No Ref
   Yes 0.761 (0.404–1.434) 0.398
Liver metastasis
   No Ref
   Yes 0.284 (0.105–0.763) 0.013 0.324 (0.115–0.915) 0.033
Baseline antibiotics
   No Ref
   Yes 1.559 (0.766–3.174) 0.221
Baseline steroids
   No Ref
   Yes 0.749 (0.461–1.218) 0.244
Tumor stage
   IB–IIIA Ref
   IIIB–IV 0.483 (0.253–0.922) 0.027
Duration of camrelizumab use
   <6 cycles Ref
   ≥6 cycles 1.974 (1.264–3.084) 0.003 1.843 (1.149–2.956) 0.011
Patterns of camrelizumab use
   Monotherapy Ref
   Plus CT 2.114 (0.895–4.995) 0.088
   Plus anti-angiogenesis 0.955 (0.303–3.009) 0.937
   Plus CT + anti-angiogenesis 1.633 (0.637–4.186) 0.307

ORR, objective response rate; NSCLC, non-small cell lung cancer; OR, odds ratio; CI, confidence interval; CT, chemotherapy.